Quashie PK - Search Results

1

Evolution of HIV integrase resistance mutations.

Quashie PK, Mesplède T, Wainberg MA. Quashie PK, et al. Curr Opin Infect Dis. 2013 Feb;26(1):43-9. doi: 10.1097/QCO.0b013e32835ba81c. Curr Opin Infect Dis. 2013. PMID: 23242340 Review.

2

A high-throughput assay for HIV-1 integrase 3'-processing activity using time-resolved fluorescence.

Han YS, Quashie P, Mesplede T, Xu H, Mekhssian K, Fenwick C, Wainberg MA. Han YS, et al. J Virol Methods. 2012 Sep;184(1-2):34-40. doi: 10.1016/j.jviromet.2012.05.003. Epub 2012 May 11. J Virol Methods. 2012. PMID: 22584270

3

Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.

Hardy I, Brenner B, Quashie P, Thomas R, Petropoulos C, Huang W, Moisi D, Wainberg MA, Roger M. Hardy I, et al. J Antimicrob Chemother. 2015 Feb;70(2):405-11. doi: 10.1093/jac/dku387. Epub 2014 Oct 3. J Antimicrob Chemother. 2015. PMID: 25281399

4

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound.

Wainberg M, Anstett K, Mesplede T, Quashie P, Han Y, Oliveira M. Wainberg M, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19518. doi: 10.7448/IAS.17.4.19518. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394027 Free PMC article.

5

HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M.

Depatureaux A, Mesplède T, Quashie P, Oliveira M, Moisi D, Brenner B, Wainberg M. Depatureaux A, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19738. doi: 10.7448/IAS.17.4.19738. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397483 Free PMC article.

6

HIV-1 Group O Resistance Against Integrase Inhibitors.

Depatureaux A, Mesplède T, Quashie P, Oliveira M, Moisi D, Plantier JC, Brenner B, Wainberg MA. Depatureaux A, et al. J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):9-15. doi: 10.1097/QAI.0000000000000698. J Acquir Immune Defic Syndr. 2015. PMID: 26017662

7

Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.

Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, Wainberg MA. Xu HT, et al. Among authors: quashie pk. J Virol. 2011 Nov;85(21):11300-8. doi: 10.1128/JVI.05584-11. Epub 2011 Aug 17. J Virol. 2011. PMID: 21849444 Free PMC article.

8

Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.

Quashie PK, Mesplède T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. Quashie PK, et al. J Virol. 2012 Mar;86(5):2696-705. doi: 10.1128/JVI.06591-11. Epub 2011 Dec 28. J Virol. 2012. PMID: 22205735 Free PMC article.

9

Novel therapeutic strategies targeting HIV integrase.

Quashie PK, Sloan RD, Wainberg MA. Quashie PK, et al. BMC Med. 2012 Apr 12;10:34. doi: 10.1186/1741-7015-10-34. BMC Med. 2012. PMID: 22498430 Free PMC article. Review.

10

Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.

Xu HT, Oliveira M, Quashie PK, McCallum M, Han Y, Quan Y, Brenner BG, Wainberg MA. Xu HT, et al. Among authors: quashie pk. J Virol. 2012 Aug;86(16):8422-31. doi: 10.1128/JVI.00271-12. Epub 2012 May 23. J Virol. 2012. PMID: 22623801 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

57 results

Search Page

Filters